Amiloride, a widely used diuretic, has multiple pharmacological actions, including inhibition of the sodium-hydronium ion and the sodium-calcium exchanger in heart. In terms of cardiac electrophysiology, amiloride prolongs action potential duration without alteration in upstroke velocity of phase 0 in Purkinje fibers. The antiarrhythmic efficacy of amiloride was assessed in a model of inducible sustained ventricular tachyarrhythmias in 16 dogs late after 2-hour occlusion-reperfusion of the left anterior descending coronary artery. Sixteen animals were studied: Four were randomly assigned to placebo, and 12 were assigned to amiloride treatment. Prolonged loading and maintenance infusions were designed to produce amiloride concentrations over the range achievable in humans. Animals were chronically instrumented to allow electrophysiological measures of conduction and refractoriness in the left ventricular infarct and border zones. Of the 12 animals treated with amiloride, six responded with inability to induce ventricular tachyarrhythmias, whereas of the four animals treated with placebo, none responded. The mean infarct size of the six animals responding to amiloride (12S5%) was significantly less than that of the six animals not responding to amiloride (20±8%). Overall, the only electrophysiological effect of amiloride observed in this study was prolongation of border zone ventricular refractoriness. This electrophysiological effect was accentuated in animals responding to amiloride. In addition, when animals were subdivided into responders, partial responders, or nonresponders, the border zone repolarization time was prolonged in responders and partial responders, whereas this measure shortened in nonresponding animals. Amiloride has antiarrhythmic activity in the suppression of sustained ventricular tachyarrhythmias in this postinfarction model. (Circulation 1988;78:1469-1477 Amiloride, a widely used diuretic, has multiple pharmacological effects on transporting epithelia, including inhibition of sodium transport, inhibition of the sodium-hydronium ion, and the sodium-calcium ion exchange systems.1-3 Inhibition of similar countertransport systems by amiloride has been reported in guinea pig heart papillary muscle, sarcolemmal membranes, and cultured heart cells.4-7 While the cellular mechanisms have not yet been fully established, amiloride has been shown to markedly prolong action potential duration without alteration in upstroke velocity of phase 0 in Purkinje fibers.8 These electrophysiological characteristics are shared by a number of highly elfective antiarrhythmic agents such as bretylium. In addition, amiloride is structurally a guanidinium, and this chemical structure is shared by a number of medications with known antifibrillatory properties including bethani-dine and meobentine (Figure 1 ).9.10 In the present study, the antiarrhythmic efficacy of amiloride at gradually increasing dosages was assessed in a model of sustained ventricular tachyarrhythmias induced by programmed electrical stimulation in 16 dogs late after myocardial infarction. The relation between antiarrhythmic activity, electrophysiological changes, and serum concentration were evaluated.
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Materials and Methods
Mongrel dogs weighing between 17 and 25 kg were anesthetized with pentobarbital followed by a mixture of nitrous oxide and halothane and ventilated with a Harvard respirator. A thoracotomy was performed in the left fifth interspace, a pericardial cradle was produced, and the left anterior descending coronary artery was dissected free at the tip of the left atrial appendage. A noose occluder was placed around the left anterior descending artery (Figure 2 ). A transient occlusion (30 seconds) was made to visualize the area of myocardium that was likely to be infarcted. Silver-silver chloride electrodes were sutured to the epicardial surface with an interelectrode distance of 5 mm: one pair in the right ventricular pulmonary outflow tract, two pairs
The guanidinium chemical group is afeature common to many known antiarrhythmic medications and amiloride.
in the center of the infarct zone, and one pair in the border zone. In addition, a quadripolar endocardial catheter was introduced through the apex of the right ventricle and manually adjusted to be in contact with the septum of the right ventricle. Transmural sutures were used to maintain this position. A heparinized end-hole catheter was placed in the right atrium and in the left ventricle. The electrode attachments and external occluder were tunneled through the muscle pairs and externalized on the back. The chest was closed in layers. After surgery, the animals were allowed to recover for 1 week. Thereafter, while the dogs were in a sedated state (diazepam), the left anterior descending coronary artery was occluded for 2 hours followed by complete reperfusion.
Protocol
Electrophysiological studies were done at least 4 days after occlusion-reperfusion. Animals were studied in a conscious but sedated state (diazepam). Each individual study consisted of a drug-free baseline evaluation to document ability to induce sustained ventricular tachyarrhythmias followed by amiloride or placebo treatment. Assignment of treatment was randomized. A set of random numbers from 1.0 to 4.99 were generated by a Texas Instruments Model 99 calculator. The sequence of drug administration was determined by these random numbers. Amiloride was given when the number selected was from 1 to 3.99, whereas placebo was given if the number was between 4.0 and 4.99. This random assignment sequence generates a probability of 25% that a dog will be treated with placebo and a 75% probability that amiloride will be assigned. Preliminary studies in two dogs assessed left ven- tricular effective refractory period over time in the border zone and showed that the electrophysiological effects of amiloride were near maximal 90 minutes after its administration. A preliminary pharmacokinetic study was performed after a 10-mg bolus of amiloride. Serum samples for analysis were drawn at 5, 15, 30, 45, 60, 90, 120, 240, and 360 minutes after the bolus dose. The negative slope (Kel) was calculated from the least-squares fit of the terminal portion of the time logarithm of concentration plot. The observed amiloride concentration time plot was best fitli to an exponential decay equation (C=Ae-at+Bet), where A was 0.196 ,ug/ml, B was 0.018 gg/ml, a was 0.03/min, and P was 0.0009/min. Figure 3 illustrates the computer simulations12 used to design the amiloride infusions. Amiloride was given as a series of loading and prolonged maintenance infusions to assess concentration-dependent changes. The contribution of each infusion (dashed line) to the net concentration produced (solid line) is shown. These infusions were designed to produce two distinct serum concentrations over the range achievable in humans.13 '14 The first loading and maintenance infusions were designed to produce serum concentrations of 60 ng/ ml. The first loading infusion consisted of 32 pg/kg/ min for 23 minutes followed by a maintenance of 3.6 gg/kg/min for 67 minutes (Figure 3 ). Electrophysiological measurements (see below) were not begun until 67 minutes after the beginning of the first maintenance infusion (90 minutes after beginning of loading infusion). If ventricular tachycardia continued to be inducible during this first maintenance infusion, then electrophysiological studies were repeated after a second series of loading and maintenance infusions. The second loading and maintenance infusions were designed to produce serum . Plot of series of loading and maintenance infusions to produce prolonged pseudo-steady-state concentrations. Low serum concentrations (target, 60 nglml) are produced by infusion rates of 32 ,uglkglmin for 23 minutes followed by 3.6 ,uglkg/min for 67 minutes, and high concentrations are produced by 70 gglkglminfor 23 minutes followed by 7.4 gglkglmin for 70 minutes.
concentrations of 150 ng/ml. The second loading of 70 ,ug/kg/min was given for 23 minutes followed by a second maintenance infusion of 7.4 ,ug/kg/min for 67 minutes. Serum samples for amiloride and electrolyte assay were obtained just before each electrophysiological study. Placebo treatments (saline) were given to four dogs over identical time periods, and the timing of electrophysiological studies was the same.
Electrophysiological Studies Each of the electrophysiological studies was divided into five portions: 1) assessment of pacing threshold, 2) intraventricular conduction, 3) ventricular refractoriness, 4) local repolarization time, and 5) the ability to induce sustained ventricular tachycardia. Extrastimuli were introduced at twicediastolic threshold and a pulse width of 2.5 msec.
Conduction time was assessed during constant rate ventricular pacing and measured as the time delay from the onset of the surface QRS to the upstroke of the five local electrograms recorded simultaneously (band width, 30-500 Hz). Conduction time was assessed when pacing from the right ventricle (normal zone), the left ventricular infarct, and the border zone. Electrograms were recorded at a paper speed of 100 mm/sec, and measurements were made from five complexes and averaged. Repolarization time was similarly assessed during constant rate ventricular pacing and measured as the electrogram "QT interval" measured from the onset of the surface QRS to the termination of T wave of the electrogram. Ventricular refractoriness was assessed with the extrastimulus technique and measured at all five bipolar electrode sites at baseline and repeated during the drug treatments.
Induction of sustained ventricular tachycardia was attempted with single, double, and triple extrastimuli introduced at twice-diastolic threshold during ventricular pacing from the right ventricular endocardial site at a cycle length of 300 msec. If sustained ventricular tachycardia was not inducible from this site, then programmed electrical stimulation was repeated while pacing from all electrode sites in the infarct zone and the border zone with the same extrastimulus protocol. The sequence of stimulation was constant and proceeded from the two endocardial right ventricular sites to the epicardial infarct sites and, finally, to the border zone. During each drug-free study, the endpoint of programmed electrical stimulation was the induction of sustained ventricular tachyarrhythmias. Inducible sustained ventricular tachycardia was defined as consecutive ventricular depolarizations at a cycle length of c400 msec elicited by programmed electrical stimulation that lasted for .30 seconds or produced hemodynamic compromise requiring immediate transthoracic cardioversion or ventricular burst pacing. If sustained ventricular tachycardia was induced that required termination by transthoracic cardioversion, 30 minutes were allowed to elapse before the next loading infusion of amiloride was begun. During subsequent drug studies, the inability to induce sustained ventricular tachycardia from all ventricular sites (same protocol as baseline) was considered complete efficacy. Partial antiarrhythmic activity was defined as an increase in the number of extrastimuli necessary to induce sustained ventricular tachyarrhythmias. Pathology
Autopsies were performed on all animals. Dogs were anesthetized with pentobarbital, and a 300-ml bolus of 10% nitro blue tetrazolium dye was given intravenously, and the heart was rapidly removed. The infarct zone and viable myocardium were distinguished by visual color analysis. The wet weights of the infarct zone and the total heart (excluding atria and large vessels) were measured and infarct size so calculated.15 Myocardial biopsies were made to assess the histology of myocardium between bipolar pairs of electrodes located in the infarct and border zone.
Biopsies were fixed in formalin, dehydrated in graded alcohols, cleaned in xylene, and embedded in paraffin wax (Surgiplast, Grays Lake, Illinois). Sections were stained with hematoxylin and eosin.
Analyses
Amiloride was quantitated with a high-performance liquid chromatography method.'6 In our laboratory, the coefficient of variability for a 100 ng/ml sample assessed serially was less than 7%. Because amiloride was the only medication that these animals received, we did not assess whether the assay would detect compounds other than diazepam. Diazepam was not detected by this assay.
Statistics
Analysis of variance was used to assess the significance of electrophysiological effects of treatments when compared with baseline. Thereafter, Duncan's multiple range test was used to compare groups. Continuous data are presented as millisecond change from baseline (mean±SD). The null hypothesis was rejected at p<0.05. To assess the concentration-antiarrhythmic effect relation, the cumulative proportion of animals responding to amiloride was related to serum concentration with both linear and nonlinear models with NONLIN. When fitting data to the Emax model, the following equation was used: Effect=E-Emax C/[EC50+C], where C is serum concentration of amiloride (ng/ml), effect is observed antiarrhythmic efficacy as defined above, Emax is the maximal antiarrhythmic efficacy, and EC50 is the concentration at which 50% of the maximal efficacy occurred.
Results
Sixteen animals were studied. Four animals received placebo treatments, whereas 12 animals received amiloride. All 16 animals had sustained ventricular tachyarrhythmias inducible during the baseline study. The mean infarct size was 17±8% in the amiloride-treated dogs and 14±5% in the placebo-treated animals (NS). Electrophysiological studies were done at least 4 days after occlusionreperfusion (mean, 8±6 days; range, 4-22 days). No relation was noted in antiarrhythmic activity of amiloride dependent on timing after infarction.
Serum Levels During Electrophysiological Studies
The serum concentrations of amiloride at electrophysiological study are shown in Table 1 . During the low-dose infusion (target, 60 ng/ml), the concentrations achieved were 107±138 ng/ml (range, 32-188 ng/ml). During the second infusion (target, 150 ng/ml), concentrations were 202±+152 ng/ml (range, 140-420 ng/ml). No significant changes were observed in serum, sodium, potassium, or magnesium concentrations (Table 1 ).
Antiarrhythmic Efficacy
During the placebo treatments, all four animals continued to have sustained ventricular tachycardia inducible. Two of these animals were inducible at baseline with the application of two extrastimuli in the left ventricle, and the other two animals required application of triple extrastimuli in the right ventricle. In this placebo group, the sustained ventricular tachyarrhythmias were terminated by burst pacing in two animals and transthoracic cardioversion in the remaining two. In no cases was placebo treatment associated with an increased number of extrastimuli required to induce ventricular tachyarrhythmias. Figure 4 reviews the results of programmed electrical stimulation in animals that received amiloride in relation to serum concentration. Complete antiarrhythmic efficacy was seen in six of the 12 animals studied. This antiarrhythmic efficacy occurred during the first maintenance infusion in five animals. The remaining responding dog had an increase in the number of extrastimuli necessary to induce ventricular tachycardia during the first maintenance infusion and complete antiarrhythmic efficacy during the second maintenance infusion. Antiarrhythmic activity was related to serum concentration with a linear model (r=0.94) and an Emax model (r=0.98). Although we have not extended our data lines beyond 300 ng/ ml in the right panel of Figure 4 , as can be seen in the left panel, two additional dogs had concentrations of more than 300 ng/ml without efficacy. Therefore, it is likely that a plateau in efficacy occurs above this concentration, and the Emax model appears a more likely biological fit. The ED50 concentration is estimated as 103 ng/ml.
The mean infarct size of animals responding to amiloride (12±5%) was significantly less than the infarct size in animals not responding to amiloride 20±8% (mean±SD, p=0.045). Partial antiarrhythmic activity was seen in an additional two animals. In the first of these two animals, three extrastimuli induced sustained ventricular tachycardia during amiloride treatment, whereas at baseline, only one extrastimulus had been necessary. In the second of these dogs, a single extrastimulus induced sustained ventricular tachyarrhythmias during amiloride treatment, whereas at baseline, ventricular pacing alone (S1SI) without extrastimulus had been necessary. Tables 2, 3 , and 4 detail the results of electrophysiological measurements at baseline and during amiloride treatment in all 12 dogs (Table 2) , during amiloride treatment in the six responding dogs (Table 3) , and during placebo (saline) treatment (Table 4 ). Significant prolongation of ventricular refractoriness in the border zone of the left ventricle occurred with amiloride in this study. This electrophysiological effect was seen for the group as a The concentration producing 50% of maximum efficacy (ED50) was 103 nglml. NZ, normal zone of right ventricle; IFZ, infarct zone of the left ventricle; BZ, border zone of the left ventricle; conduction time IFZ to IFZ, conduction delay from the onset of the QRS on the surface electrocardiogram to the upstroke of the electrogram recorded in the IFZ during IFZ pacing; conduction time IFZ to NZ, conduction delay from the onset of the surface QRS to the upstroke of the electrogram recorded in the NZ during pacing of the IFZ; conduction time NZ to BZ, time delay from the onset of the surface QRS to the upstroke of the electrogram recorded in the BZ during pacing of the NZ; VERP, ventricular effective refractory period. 275±12 NZ, normal zone of right ventricle; IFZ, infarct zone of the left ventricle; BZ, border zone of the left ventricle; conduction time IFZ to IFZ, conduction delay from the onset of the QRS on the surface electrocardiogram to the upstroke of the electrogram recorded in the IFZ during IFZ pacing; conduction time IFZ to NZ, conduction delay from the onset of the surface QRS to the upstroke of the electrogram recorded in the NZ during pacing of the IFZ; conduction time NZ to BZ, time delay from the onset of the surface QRS to the upstroke of the electrogram recorded in the BZ during pacing of the NZ;vERP, ventricular effective refractory period. whole, and changes were greater in animals responding to amiloride. However, prolongation of border zone ventricular effective refractory period did not clearly discriminate responding from nonresponding animals. For example, one responding animal had only a 5-msec prolongation in border zone refractoriness, whereas an animal with no antiarrhythmic activity had a 20-msec prolongation.
Electrophysiological Responses
Although border zone repolarization time was not significantly prolonged for the group as a whole, prolongation did occur in subsets of animals. The border zone repolarization time prolonged in animals at the dose of amiloride producing complete or partial antiarrhythmic activity (255±16 msec at baseline, 269±15 msec during amiloride; p<0.05) and shortened in animals without antiarrhythmic activity at the highest dosage tested (261±21 msec at baseline, 256±24 msec during amiloride; NS). No significant electrophysiological changes were seen during placebo treatment.
Pathology
To assess the histology of the myocardium underlying the border and infarct zone electrodes, biopsies of these areas were obtained in five animals. In all five animals, the histology of the infarct zone consisted of a patchy myocardial necrosis with mononuclear cell infiltration at 10 days after infarction ( Figure 5A ). As can be seen in Figure 5B , a similar pattern was seen in four of five dogs in the border zone; however, the extent and intensity of infarction was substantially less. In one animal, the histology of the border zone showed minimal patchy fibrosis without evidence of infarction in this zone.
Discussion
The present study was designed to assess the electrophysiological and antiarrhythmic effects of amiloride. Antiarrhythmic efficacy was established in this study by a number of criteria. First, baseline drug-free studies were done to confirm the ability to induce sustained ventricular tachyarrhythmias immediately before amiloride treatment. Second, the electrophysiological responses to amiloride were compared with those seen in placebo-treated animals. Finally, concentration-response relations were systematically assessed. In this study, amiloride was found to have antiarrhythmic activity in 50% of the animals evaluated. We have previously assessed the antiarrhythmic efficacy of more conventional antiarrhythmic drugs in this same model with an identical protocol. The antiarrhythmic efficacy of quinidine and mexiletine in this model are 10% and 0%, respectively.17 Therefore, the antiarrhythmic efficacy of amiloride in this model seems substantially more than that seen with some conventional antiarrhythmic drugs.
This study does not directly address the cellular mechanisms by which amiloride prolongs border zone repolarization time and refractoriness. Many mechanisms can be postulated to explain prolongation of repolarization time. First, an electrogenic Na-Ca exchange mechanism may be operative during the plateau of the action potential, and blockade of this exchanger has been reported to prolong action potential duration. 18 Second, amiloride has been shown to cause intracellular acidification in Purkinje fibers of up to 0.2 pH units. 19, 20 Intracellular acidification can block the inwardly rectifying potassium current.21 Blockade of the inwardly rectifying potassium current would be expected to prolong action potential duration. We speculate that acidification of cells may be accentuated in viable but physiologically abnormal cells bordering the infarct zone. This may explain the selectivity of amiloride's electrophysiological effects occurring in the border zone. In addition, intracellular acidification alters inactivation of the sodium channel21 and thereby may affect refractoriness.
The in vivo electrophysiological effects of amiloride seen in the present study are different than those reported in vitro.8 Marked action potential duration prolongation was reported in vitro8; we observed only small changes in the electrogram repolarization times, and these were limited to the border zone. These differences may relate to the cycle length of stimulation used and the amiloride concentration range tested in the present study. In the study of Marchese et al,8 the prolongation of action potential duration seen with amiloride in vitro was frequently dependent. Maximum prolongation of action potential was observed while pacing at a cycle length of 2,000 msec, whereas at a more physiological pacing cycle length (500 msec), extent of prolongation was substantially less. The cycle length of ventricular stimulation in this study (300 msec) was less than that used in the in vitro studies (500-2,000 msec). 8 The cycle length of stimulation in this study was chosen to avoid sinus node competition during ventricular pacing. A second difference between the present study and that of Marchese et a18 is that the concentrationresponse relations assessed in the in vitro studies were done over a range of concentrations from 1 to 10 ,uM. Little change in action potential duration was seen in vitro at 1 p.M. The concentration range studied in the present study (0.1-0.3 ,uM) was designed to mimic concentrations that have been seen in humans. 13, 14 This concentration range is substantially less than that used in the in vitro studies. A final difference may relate to the tissues studied. In the present study, electrophysiological effects on the ventricular muscle in vivo were assessed, whereas Marchese et a18 assessed Purkinje fibers in vitro.
The mean infarct size in animals responding to amiloride was significantly less than in the animals not responding to amiloride. However, the infarct size of placebo-treated animals, 14±5%, was not significantly different from that in animals responding to amiloride. Therefore, the antiarrhythmic efficacy of amiloride in this group cannot be attributed to the small infarct size alone. This study does not address the mechanism underlying why animals with larger infarcts are less likely to respond to amiloride.
This study has many limitations. First, amiloride has multiple pharmacological effects. This study does not define the cellular mechanism(s) of amiloride that mediate its electrophysiological and antiarrhythmic actions. Although amiloride prolongs border zone refractoriness and repolarization time, we have no evidence that these electrophysiological changes cause the antiarrhythmic efficacy. In addition, because of the relatively small number of animals studied, type II errors are possible, and other significant electrophysiological changes may occur that were not recognized in this study. However, no other trends are evident that approach statistical significance. Second, the relation between arrhythmias induced in this dog model to those seen in humans is uncertain. However, in our previous studies, the antiarrhythmic efficacy of mexiletine and quinidine in this canine model generally parallel their antiarrhythmic activity in humans. 16 A further technical limitation relates to measurement of electrogram repolarization time. Subtle changes in the terminal portion of phase 3 repolarization of an action potential may have major effects on the timing of sodium channel recovery. Such subtle changes may not be measureable with this in vivo measurement of electrogram repolarization time. This is particularly true in that electrogram signals in this study were filtered and some loss of low frequency information is possible.
In conclusion, amiloride has antiarrhythmic activity in the suppression of sustained ventricular tachyarrhythmias in this postinfarction model. Studies appear indicated to establish the antiarrhythmic efficacy of amiloride in humans.
